These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 30099637)

  • 21. Path of least recurrence: A systematic review and meta-analysis of fidaxomicin versus vancomycin for Clostridioides difficile infection.
    Liao JX; Appaneal HJ; Vicent ML; Vyas A; LaPlante KL
    Pharmacotherapy; 2022 Nov; 42(11):810-827. PubMed ID: 36223209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study.
    Gentry CA; Campbell DL; Williams RJ
    Int J Antimicrob Agents; 2021 Mar; 57(3):106282. PubMed ID: 33465458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
    Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
    J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain.
    Rubio-Terrés C; Cobo Reinoso J; Grau Cerrato S; Mensa Pueyo J; Salavert Lletí M; Toledo A; Anguita P; Rubio-Rodríguez D; Watt M; Gani R
    Eur J Clin Microbiol Infect Dis; 2015 Nov; 34(11):2213-23. PubMed ID: 26407619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis.
    Bauer MP; Hensgens MP; Miller MA; Gerding DN; Wilcox MH; Dale AP; Fawley WN; Kuijper EJ; Gorbach SL
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S149-53. PubMed ID: 22752864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An antimicrobial stewardship program's real-world experience with fidaxomicin for treatment of Clostridium difficile infection: a case series.
    Vargo CA; Bauer KA; Mangino JE; Johnston JE; Goff DA
    Pharmacotherapy; 2014 Sep; 34(9):901-9. PubMed ID: 24898525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful Fidaxomicin Hospital Discharges of Adult Patients With Clostridioides difficile Infections Post-2021 Guidelines: Are Economic Barriers Finally Coming Down?
    Fang N; Ha D; Dong K; Leung T; Lee S; Holubar M; Meng L
    Clin Infect Dis; 2022 Aug; 75(3):519-521. PubMed ID: 34971358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of Clostridioides difficile infections treated in a Swiss tertiary care hospital: an observational study.
    Haubitz S; Bartlomé N; Bucheli Laffer E; Spelters C; Fankhauser H; Fux CA
    Swiss Med Wkly; 2020 Jan; 150():w20173. PubMed ID: 31940431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fidaxomicin--the new drug for Clostridium difficile infection.
    Vaishnavi C
    Indian J Med Res; 2015 Apr; 141(4):398-407. PubMed ID: 26112840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection.
    Nathwani D; Cornely OA; Van Engen AK; Odufowora-Sita O; Retsa P; Odeyemi IA
    J Antimicrob Chemother; 2014 Nov; 69(11):2901-12. PubMed ID: 25096079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model.
    Warren CA; van Opstal E; Ballard TE; Kennedy A; Wang X; Riggins M; Olekhnovich I; Warthan M; Kolling GL; Guerrant RL; Macdonald TL; Hoffman PS
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4103-11. PubMed ID: 22585229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-life experience with fidaxomicin in Clostridioides difficile infection: a multicentre cohort study on 244 episodes.
    Escudero-Sánchez R; Valencia-Alijo A; Cuéllar Tovar S; Merino-de Lucas E; García Fernández S; Gutiérrez-Rojas Á; Ramos-Martínez A; Salavert Lletí M; Castro Hernández I; Giner L; Cobo J
    Infection; 2021 Jun; 49(3):475-482. PubMed ID: 33417171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With Clostridium difficile Infection.
    Stevens VW; Nelson RE; Schwab-Daugherty EM; Khader K; Jones MM; Brown KA; Greene T; Croft LD; Neuhauser M; Glassman P; Goetz MB; Samore MH; Rubin MA
    JAMA Intern Med; 2017 Apr; 177(4):546-553. PubMed ID: 28166328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.
    Miller M
    Expert Opin Pharmacother; 2010 Jun; 11(9):1569-78. PubMed ID: 20446864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital.
    Pichenot M; Héquette-Ruz R; Le Guern R; Grandbastien B; Charlet C; Wallet F; Schiettecatte S; Loeuillet F; Guery B; Galperine T
    Infection; 2017 Aug; 45(4):425-431. PubMed ID: 28120176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany.
    Watt M; McCrea C; Johal S; Posnett J; Nazir J
    Infection; 2016 Oct; 44(5):599-606. PubMed ID: 27062378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
    Crawford T; Huesgen E; Danziger L
    Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.
    van Prehn J; Reigadas E; Vogelzang EH; Bouza E; Hristea A; Guery B; Krutova M; Norén T; Allerberger F; Coia JE; Goorhuis A; van Rossen TM; Ooijevaar RE; Burns K; Scharvik Olesen BR; Tschudin-Sutter S; Wilcox MH; Vehreschild MJGT; Fitzpatrick F; Kuijper EJ;
    Clin Microbiol Infect; 2021 Dec; 27 Suppl 2():S1-S21. PubMed ID: 34678515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fidaxomicin for the treatment of Clostridium difficile infections.
    Whitman CB; Czosnowski QA
    Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.
    Crook DW; Walker AS; Kean Y; Weiss K; Cornely OA; Miller MA; Esposito R; Louie TJ; Stoesser NE; Young BC; Angus BJ; Gorbach SL; Peto TE;
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S93-103. PubMed ID: 22752871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.